Other Expenses
Other expenses consist primarily of general and administrative costs, insurance costs, travel costs and other office and office related activities. Other expenses were negligible during the years ended 2021 and 2022.
Net Loss
Our net loss was $(10,547,755) for the twelve months ended December 31, 2022, compared to $(5,305,959) for the twelve months ended December 31,2021. This increase in net loss is reflective of the rapid growth of our Company and accompanying investment by management, including increased employee count, technology development, construction and deployment of pilot plants and other related costs and expenses.
Liquidity and Capital Resources
Since our inception in 2018, we have devoted most of our cash resources to employees, consultants, professional services and research and development activities to develop and grow our business. We have financed our operations to date primarily with the use of proceeds from the Founders’ capital, a Series A Preferred Stock offering, a Series B Preferred Stock offering, Regulation CF offerings, a Regulation A+ offering, and convertible promissory notes.
To date, we have not generated any revenue from technology service fees or product sales, and we do not anticipate generating any revenue from the sale of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. During the period from December 2018 (inception) through December 31, 2022, we have incurred cumulative net losses of approximately $18.4 million. Our future expenditures and capital requirements will depend on numerous factors, including, among others, the progress of our research and development efforts, deployment of pilot plants with key customers, and our ability to scale up to commercial operations.
Through the date of this Annual Report, we have raised capital by exempt offerings of common stock, preferred stock and convertible notes of approximately $40 million, net of offering costs and commissions.
During the years ended December 31, 2020, December 31, 2021 and December 31, 2022, on various dates, the Company financed its operations through the exempt sale of promissory notes convertible to common stock under the registration exemption provided by Section 4(a)(2) of the Securities Act, raising an aggregate of $6,871,330. The net proceeds of the offerings were deployed for general corporate purposes, intellectual property, pilot plants, and battery design operations. All of the Company’s convertible promissory notes have been converted as of December 31, 2022.
From February 2021 to September 2021, the Company offered its Common Stock through a registered funding portal Netcapital in a side-by-side offering of Common Stock, under registration exemptions Section 4(a)(6) and Regulation D, Rule 506(c), raising an aggregate of $4,465,844. The net proceeds of the offering were deployed for general corporate purposes, intellectual property, pilot plants, battery design operations.
On April 1, 2021, the Company completed a Regulation D, Rule 506(b) exempt equity financing issuing 3,407,142 shares of Preferred Series A stock for total proceeds of $5,565,000 before fees and commissions. The net proceeds of the offering were deployed for general corporate purposes, intellectual property, pilot plants, battery design operations.
In September 2022, the Company completed a Regulation A+, Tier 2 equity financing issuing 1,126,837 shares of Common Stock for total proceeds of $6,896,192 before fees and commissions. The net proceeds of the offering are being deployed for demonstration plant and commercial deployment, Litas Technology, manufacturing, SoLis Battery Technology, laboratory & production facility, research and development, and general and administrative purposes.
In December 2022, the Company completed the first closing of its Regulation D, Rule 506(b) exempt Series B Preferred Stock offering with GM Ventures, LLC and Eni Next issuing 3,750,000 shares of Preferred Series B Stock for total proceeds of $15,000,000 before fees and commissions, as well as converting approximately $4,800,000 of convertible notes to Series B Preferred Stock at a 15% discount. The net proceeds of the offering are to be deployed for demonstration plant and commercial deployment, Litas Technology, manufacturing, SoLis Battery Technology, laboratory & production facility, research and development, and general and administrative purposes.
These funds have provided us the ability to complete pilot plants that we have deployed to our customers in South America as well as advance our work on the demonstration and commercial facilities that are scheduled to be designed and completed in 2024. We continuously monitor our use of funds relative to executing on our business strategy with a focus on spending capital that will further our ability to recognize revenue in the future. We balance our use of funds based on our ability to raise additional capital resources through various exempt offerings.
We believe that we currently have sufficient capital to finance our operations at least through the end of 2023. However, if our operating and development costs are higher than expected, we will need to obtain additional financing prior to that time. Further, we expect that, after such period, we will be required to raise additional capital to fund our operations and to further advance the commercialization of LiTAS™ in South America and the US. There is no assurance that such financing will be available when needed, or that ultimately, we will achieve profitable operations and positive cash flow.
5